Submitted by InStockRx, AAP Preferred Partner
Walk into almost any independent pharmacy, and somebody can point you to the shelf. It is usually toward the back. A few bottles of something a prescriber moved a patient off of last spring. A bulk buy that looked smart in March. Something seasonal that never went anywhere. Nobody planned it. Nobody has time for it.
Every pharmacy generates surplus. It is a normal cost of carrying inventory against demand you cannot perfectly predict. What separates pharmacies is not whether they have a surplus shelf; it is whether they work it on purpose or discover it during an audit.
This is a practical look at what surplus actually is, what your options are, and what the rules require when medication moves between pharmacies.
Where surplus comes from
Four sources account for most of it. Therapy changes, where a prescriber switches a patient, and the remaining supply has no other home. Overbuying, usually against a deal or a shortage that resolved faster than expected. Seasonal miscalls, which are obvious in hindsight and invisible in August. And slow attrition: the product that sold twice a year and then stopped.
None of these mean anything went wrong. They mean you carried inventory. The question is what happens next.
Your three real options, and when each is right
Return to the wholesaler comes first, and it is the cleanest path when the product qualifies. Manufacturer and wholesaler return policies vary widely on dating windows, restocking fees, and which products are returnable at all. Specialty, refrigerated, and short-dated items are the common exclusions. Check the policy before you assume something is returnable, because the answer changes by manufacturer and sometimes by contract.
Reverse distribution is the right path for expired, recalled, damaged, and otherwise non-salable product. It exists to get that material destroyed properly and documented. It is not built for speed or for value recovery, and using it that way is where pharmacies lose money. Credits can take weeks or a quarter, fees come off the top, and the return on in-date product is usually a fraction of acquisition cost.
Transferring or selling to another pharmacy is the third option, and it is the one most owners use least. It only applies to in-date, salable product, and it only works when somebody else actually needs that NDC. Done well, it returns more than a reverse-distribution credit and returns it sooner. Done casually, it creates a recordkeeping problem.
What the rules require when product moves pharmacy to pharmacy
DSCSA covers pharmacy-to-pharmacy transfers, not only wholesaler shipments. There is one narrow exception worth knowing precisely: a dispenser may transfer product to another dispenser to fill a prescription for a specific identified patient. FDA is explicit that the exception does not cover transfers made to build stock levels.[1] So the one-off transfer to help a colleague fill a script tonight sits in a different category from selling surplus, and only the first one is exempt.
Most pharmacists still call the paperwork T3, meaning transaction information, transaction history, and transaction statement. That shorthand has aged out. As of November 27, 2023, section 582(k)(1) ended the requirement for trading partners to pass transaction history.[2] What moves now is the transaction information and the transaction statement, at the package level, carrying the product identifier: standardized numerical identifier, lot number, expiration date. History still matters during a recall or investigation, and you still have to be able to trace back toward the manufacturer. It is simply no longer handed over on every sale.
On retention, FDA guidance sets the period at not less than six years from the date of the transaction.[3] That is the floor, and it applies whether the records live in a system or a filing cabinet.
Which deadline actually applies to you
The electronic, interoperable version of these requirements took effect November 27, 2023, but not every pharmacy is on the same clock. FDA has exempted small dispensers, and where applicable their trading partners, until November 27, 2027.[4] A small dispenser is one whose owning company has 25 or fewer full-time employees licensed as pharmacists or qualified as pharmacy technicians, counted as of November 27, 2026.[4] Most independents fall inside that definition.
Be precise about what the exemption does. It does not switch off the underlying obligations. Exempted pharmacies still capture transaction information, still verify products, still gather recall information, still respond to regulators. What it permits is manual or existing methods rather than electronic interoperable ones.[4] If you are planning a system change in the next two years, that is the date to plan against, and it is worth confirming your own status rather than assuming it.
Cold chain and controlled substances
Refrigerated product needs validated packaging and a documented temperature record from the moment it leaves your hands. Controlled substances carry separate DEA transfer requirements, and your state board may add its own. Neither is a reason to avoid surplus recovery, but both need to be settled before anything ships, not after.
Building a workflow that actually runs
Surplus has value while it still has shelf life. Wait long enough, and the only remaining option is the one that pays least. A workable filter is anything that has not moved in ninety days, plus anything dating within six months, reviewed on the same day every month so it happens at all.
Then do the arithmetic on your own shelf rather than on an industry average. For five real NDCs, compare what a wholesaler return would credit, what reverse distribution would net, and what a direct sale would return, and put a value on how long each takes. Cash this month is worth more than a credit next quarter, and the gap widens if you are financing inventory. Most owners find the spread is wider than they assumed, particularly on brand and specialty.
How to evaluate any channel you are considering
Whatever route you use, the same questions apply. Ask how licensure is verified and whether you can see who is on the other side of a transaction. Ask whether the transaction record is created automatically or whether you have to request it later, and whether you can export your own records without asking permission. Ask how long records are retained. Ask what happens if a shipment arrives short or damaged, and who resolves it.
Ask one more that owners often skip: what happens when a PBM opens an inquiry eight months later. Find out whether you are assembling that response alone before you are in the position of assembling it alone.
Ask to see a sample transaction record before you list anything. Any legitimate operation will show you one.
Marketplaces built for pharmacy-to-pharmacy trading are one way to handle the third option at scale; InStockRx is one example. Group purchasing organizations have also begun offering members private versions of these marketplaces so trading stays within a known group.
None of this replaces reverse distribution. Expired and non-salable product still goes back, and should. The narrower and more useful point is that a real share of what pharmacies write off is in-date product somebody else needs, and a real share of what pharmacies cannot source is sitting on a shelf across the state.
The surplus shelf is not only a cost to manage. With a regular cadence, documentation discipline, and a clear view of which of the three options fits each item, it becomes recovered cash and one less box of usable medicine headed for destruction.
Sources:
[1] FDA, Drug Supply Chain Security Act Product Tracing Requirements: Frequently Asked Questions. fda.gov/drugs/drug-supply-chain-security-act-dscsa/drug-supply-chain-security-act-product-tracing-requirements-frequently-asked-questions
[2] FDA, DSCSA Standards for the Interoperable Exchange of Information for Tracing of Certain Human, Finished, Prescription Drugs. fda.gov/media/171796/download
[3] FDA, DSCSA Implementation: Product Tracing Requirements for Dispensers. fda.gov/media/92650/download
[4] FDA, Exemptions under the Drug Supply Chain Security Act. fda.gov/drugs/drug-supply-chain-security-act-dscsa/exemptions-under-drug-supply-chain-security-act (verified August 29, 2026)
InStockRx is a marketplace where verified, licensed U.S. pharmacies buy and sell prescription medication directly with one another. More than 1,800 verified pharmacies use it to turn overstock into cash and to source hard-to-find brand and specialty medications from peers. As an AAP preferred partner, InStockRx powers the InStockRx/AAP Marketplace, a private marketplace for AAP Members. Every Member is a licensed, DEA-registered U.S. pharmacy verified before trading, counterparties are visible, and every transaction carries exportable documentation retained for seven years. Free to sign up, with a 10% seller fee only when an item sells. pharmacy-https://admin.instockrx.com/create-account